The alliance will use Oxford BioDynamics’ EpiSwitch high-throughput technology to develop a biomarker assay for the blood-based diagnosis of the neurodevelopmental condition.
EpiSwitch is designed to enable the discovery, evaluation, validation and monitoring of a new type of epigenetic biomarkers called chromosome conformation signatures (CCSs).
According to the agreement, Casa Sollievo della Sofferenza will supply blood samples from autistic patients, as well as healthy controls. The EpiSwitch technology will then be used to screen these samples for epigenetic changes in the form of CCSs.
